5th International Meeting on Aortic Diseases

New insights into an old problem

CHU Liège, APF

September 15-17 2016

Crowne Plaza Hotel Liège, Belgium

www.chuliege-imaa.be
Under the patronage of:

- University of Liège
- Cardiovascular Surgery Department of CHU of Liège
- Province of Liège
- APF (Aneurysmal Pathology Foundation)
- Faculty of Medicine, ULg

Course Director:
Natzi SAKALIHASAN
Liège, Belgium

Co-Director:
Jean-Olivier DEFRAGNE
Liège, Belgium

Scientific Committee:
Matt BOWN
Cardiff, United Kingdom
Audrey COURTOIS
Liège, Belgium
Alessandro DELLA CORTE
Napoli, Italy
John ELEFTERIADES
New Haven, USA
Rebecka HULTGREN
Stockholm, Sweden
Gregory JONES
Dunedin, New Zealand
Nicos LABROPOULOS
Stony Brook, USA
Frank LEDERLE
Minneapolis, USA
Victor LEGRAND
Liège, Belgium
Christoph NIENABER
London, United Kingdom
Florence PINET
Lille, France
Marc RADERMECKER
Liège, Belgium

Juliette ALBUSSON,
Paris, France
Eric ALLAIRE,
Créteil, France
Valery ARAKELYAN,
Moscow, Russia
George ASIMAKOPOULOS,
Bristol, United Kingdom
Parla ASTARCI,
Bruxelles, Belgium
Domenico BACCHELLIERI,
Milan, Italy
Jean-Pierre BEQUEMIN,
Champigny, France
Yadav BHATTA,
Kathmandu, Nepal
Colin BICKNELL,
London, United Kingdom
Malenka BISSELL,
Oxford, United Kingdom
Jan D. BLANKENSTEIJN,
Amsterdam, The Netherlands
Simon BODY
Boston, USA
Jan BRUNKWALL,
Köln, Germany
Rachel CLOUGH,
London, United Kingdom
Ronald DALMAN,
Stanford, USA
Lazar B. DAVIDOVIC,
Suncin, Serbia
Julie DE BACKER,
Gent, Belgium
Frédéric COLLART,
Marseille, France
Jean-Paul DE VRIES,
Nieuwegein, The Netherlands
Barry DOYLE
Perth Australia
Helena DULGHERU,
Liège, Belgium
Rodolphe DURIEUX,
Liège, Belgium
Hans-Henning ECKSTEIN,
Munch, Germany
Sean ENGLISH,
St Leuas, USA
Per ERIKSSON,
Stockholser, Sweden
Daniel FINK,
Jerusalem, Israel
Peter FRAMBACH,
Luxembourg
Julien GAER,
Harefield, United Kingdom
Christian GASSER,
Stockholm, Sweden
Athanasios GIANNOUKAS,
Larissa, Greece
Evaldas GIRDASUKAS,
Bad Berka, Germany
Jonathan GOLLEDGE,
Townsville, Australia
David GUZZARDI
Calgary, Canada
Grégoire HANS,
Liège, Belgium
Dominic HOWARD,
Oxford, United Kingdom

INVITED FACULTY

- Heinz JAKOB, Essen, Germany
- Fabien KOSKAS, Paris, France
- Dung LE HUU, Ho Chi Minh, Vietnam
- Jan LINDEMAN, Leiden, The Netherlands
- Jes LINDHOLT, Viborg, Denmark
- Bart LOEYS, Antwerp, Belgium
- Lars MAEGDEFESSEL, Stockholm, Sweden
- Miltiadis MATSAKGAS, Larissa, Greece
- Bart MEURIS, Leuven, Belgium
- Jean-Baptiste MICHEL, Paris, France
- Rita MILEWSKI, Philadelphia, USA
- Thomas MODINE, Lille, France
- Firas MUSSA, New York, USA
- Paul NORMAN, Fremantle, Australia
- Betty NUSGENS, Liège, Belgium
- Öztekin OTO, Izmir, Turkey
- Domenico PALOMBO, Genova, Italy
- Luc PIERARD, Liège, Belgium
- Janet POWEL, London, United Kingdom
- Cesare QUARTO, London, United Kingdom
- Morgan SALMON, Charlottesville, USA
- Thanos SARATZIS, Leicester, United Kingdom
- Toru SUZUKI, Leicester, United Kingdom
- Apostolos TASSIOPOULOS, Stony brook, USA
- Vincent TCHAN SATO, Liège, Belgium
- Gilbert R. UPCHURCH, Charlottesville, USA
- Rao Srinivasa VALLABHANENI, Liverpool, United Kingdom
- Isabelle VAN HERZEELE, Gent, Belgium
- Eric VERHOEVEN, Nürnberg, Germany
- Emiliano VOTTA, Milan, Italy
- Pascal VRANCKX, Hasselt, Belgium
- Anders WANHAINEN, Uppsala, Sweden
- James YEH, London, United Kingdom
- Koichi YOSHIMURA, Yamaguchi, Japan
<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday September 15</th>
<th>Friday September 16</th>
<th>Saturday September 17</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Genetics of aortic diseases</td>
<td>Aortic dissection</td>
<td>Risk stratification in BAV aortopathy: new concepts</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
<td>Coffee break</td>
<td>08.30</td>
</tr>
<tr>
<td>10.30</td>
<td>Epidemiology and treatment of AAA</td>
<td>Challenging cases of aortic dissection</td>
<td>09.45</td>
</tr>
<tr>
<td>10.45</td>
<td>Coffee break</td>
<td>10.00</td>
<td>10.15</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
<td>Lunch break</td>
<td>11.30</td>
</tr>
<tr>
<td>13.30</td>
<td>New advances in physiopathology of aortic diseases</td>
<td>13.30</td>
<td>Industry sponsored symposium</td>
</tr>
<tr>
<td>15.00</td>
<td>Generalities on medical treatment of AAA</td>
<td>15.00</td>
<td>12.30</td>
</tr>
<tr>
<td>15.45</td>
<td>Coffee break</td>
<td>16.40</td>
<td>13.30</td>
</tr>
<tr>
<td>17.15</td>
<td>Causes and management of ruptured AAA</td>
<td>17.10</td>
<td>13.30</td>
</tr>
<tr>
<td>19.05</td>
<td>End of the sessions</td>
<td>End of the sessions</td>
<td>15.00</td>
</tr>
</tbody>
</table>

20.00 IMAD Official dinner - Thursday
Palais Provincial
All delegates are welcome to register with one guest. Seated dinner.
Participation fee: 55 € per person.
Thursday September 15

08.00  Welcome address, Natzi Sakalihasan
       Distinguished lecture, Frank Lederle

08.30  Extra-aortic cardiovascular features in Marfan syndrome - Relevance and management, Julie De Backer
08.38  Whole blood DNA methylation analysis in AAA; an epigenome-wide association study, Greg Jones
08.46  Combining Mendelian genetics and genetic epidemiology for AAA, Juliette Albuisson
08.54  New insights on genetic aspect of aortic disease, John Elefteriades
09.02  Does sex matter in aortic aneurysm and dissection? Bart Loeys
09.10  Genetic risk profile: insights from family based AAA NGS analysis, Danielle Majoor, Arne S. Ijpma
09.26  Discussion

09.35  Short communications from selected papers
09.35  High heritability of abdominal aortic aneurysms - a population-based twin-study, Trine Maria Mejnert Joergensen
09.40  Global and gene specific DNA methylation is associated with Abdominal Aortic Aneurysms, Bradley Topgli
09.45  End-stage human aneurysm disease in different arterial positions is similar – aneurysm induction in mouse models however not, Albert Busch
09.50  Phenotypic switching of SMCs is a potential therapeutic target in popliteal aneurysms, Albert Busch
09.55  Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model, Vivian de Waard

10.00  Coffee break

10.30  Epidemiology and treatment of AAA
       Frank Lederle, Anders Wanhainen
10.40  Findings from the Swedish AAA screening program, Anders Wanhainen
10.50  Morphology of ruptured vs unruptured AAA, Janet T. Powell
11.00  AAA rupture in Stockholm, Rebecka Hultgren
11.10  Australian trials to identify treatments to slow AAA growth, Jonathan Golledge
11.20  AAA measurement and enlargement, Frank Lederle
11.30  CT-overestimation of AAA size severely impacts the cost-effectiveness of AAA repair, Jan Lindeman
11.40  Discussion

12.10  Short communications from selected papers
12.10  Immunopathology in patients with AAA, Miroslav Prucha
12.15  How does it feel to have an abdominal aortic aneurysm – a patient-centered view, Stephanie Tomee
12.20  Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women, Pinar Ulug
12.25  Diameter growth rate and future indication for surgery can be predicted with finite element analysis and semi-automatic diameter measurements in small abdominal aortic aneurysms, Moritz Lindquist Liljeqvist
12.30  Lunch break

12.30  New advances in physiopathology of aortic diseases
       Audrey Courtois, Florence Pinet
13.30  Inward neo-angiogenesis in aortic diseases, Jean-Baptiste Michel
13.38  NETosis is associated with abdominal aortic aneurysm rupture, Sean English
13.46  The translational story of the relationship between reversible pulmonary obstructive disease and AAA, Jes Lindholt
13.54  Non-coding RNA and aneurysm, clinical implications: form experimental animal models to therapeutics approaches, Lars Maegdefessel
14.02  Cell-specific expression of non coding RNA in human AAA: new approach to find biomarkers, Florence Pinet
14.10  Circulating miRNA associated with unstable abdominal aortic aneurysm PET positive, Audrey Courtois
14.18  Circulating vascular basement fragments are associated with the diameter of abdominal aorta, Anders Wanhainen
14.26  Discussion

14.50  Short communications from selected papers
14.50  Transdifferentiation of human dermal fibroblasts to smooth muscle like cells: a novel method to study the effect of MYH11 and ACTA2 variants in the aortic aneurysm wall, Natalija Bogunovic
14.55  Live human arterial tissue slices for bench top research on pathophysiology of aortic aneurysms; up to 90 days ex vivo preservation, Jorn Meekel
Thursday September 15

I Generalities on medical treatment of AAA
Gilbert R. Upchurch, Paul Norman
15.10 Where and why does thrombus develop in aortic disease, Barry Doyle
15.18 Focal adhesion Kinase is a novel target for pharmacotherapy of abdominal aortic aneurysm, Koichi Yoshimura
15.26 Inhibition of aneurysmal progression by local PGG infusion in experimental porcine AAA, Jes Lindholt
15.34 Telmisartan in the management of abdominal aortic aneurysm (TEDY): the study protocol for a randomized controlled trial, Jonathan Golledge
15.42 What is the role of the KLF4 during the development of abdominal aortic aneurysm, Morgan Salmon
15.50 What do we know about AAA and diabetes and does it matter? Paul Norman
16.06 Keynote lecture. Medical treatment of the AAA in human. Fiction or reality? Gilbert R. Upchurch
16.14 Discussion
Short communications from selected papers
16.30 • Inhibition of pathological vascular smooth muscle cell remodelling as a treatment strategy for abdominal aortic aneurysm, Marc Bailey
16.35 • Canonical TGFβ-signalling is triggered by inflammation in human non-syndromic aneurysm disease, but is not reflected by inducible AAA mouse models, Albert Busch
16.40 • Phenotyping of transgenic pigs to determine the suitability of xenografts in the treatment of aortic diseases, Ewa Strauss
16.45 Coffee break

I Causes and management of ruptured AAA
Rebecka Hultgren, Ronald Dalman
17.15 The biology of AAA progression and rupture: beyond MMPs and inflammation, Jan Lindeman
17.23 Imaging alternatives in order to prevent rupture [volume vs diameter], Christian Gasser
17.31 Is the risk different for female or male FDRs to AAA patients? Rebecka Hultgren
17.39 Emergency EVAR - the new standard for almost every patient with a ruptured AAA (technique and own clinical data over 10 years, literature review), Hans-Henning Eckstein
17.47 Open repair of RAAA is always possible - is it always better? Lazar Davidovic
17.55 Prolonged or renewed ICU stay after AAA-repair - a "crash investigation", Anders Wanhainen
18.03 TAVI, MAVI, TEVAR, EVAR - The end of standard cardiovascular surgery? Perspectives of a cardiac surgeon, Daniel Fink
18.11 Staged hybrid repair of extensive TAAA, Gilbert R. Upchurch
18.19 Keynote lecture. Lessons learned from IMPROVE trial, Janet T. Powell
18.27 Questions to experts & panel discussion
Short communications from selected papers
18.40 • Management of visceral artery aneurysms: a 20-year single centre experience, Gianfranco Filippone
18.45 • Aortic size index could improve surveillance of women and men with AAA, Rebecka Hultgren
18.50 • How common is the classic triad of symptoms in patients with ruptured AAA? Rebecka Hultgren
18.55 • Survival disparity following AAA repair highlights inequality in socioeconomic status, Manar Khashram
19.00 • Patient reported quality and functional life after AAA repair, Manar Khashram
19.05 End of the sessions
20.00 Official dinner (upon registration)
Friday September 16

Aortic dissection
Natzi Sakalihasan, Christoph Nienaber
08.30 Diagnostic algorithm for acute aortic dissection – imaging and biomarkers, Toru Suzuki
08.40 Therapeutic pathways in acute aortic dissection, Cesare Quarto
08.50 Individualized risk assessment in type B aortic dissection, Rachel Clough
09.10 Computational modelling of type B aortic dissection: does it help manage patients? Barry Doyle
09.20 Initial experience in dissection of aorta in Nepal, Yadav Bhatta
09.30 Keynote lecture. Christoph Nienaber
09.40 Discussion
10.00 Coffee break

Challenging cases of aortic dissection
Firas Mussa, Jean-Olivier Defraigne
10.30 Aortic dissection – the great masquerader, James Yeh
10.40 Proximal aortic dissection – the role of the frozen elephant, Heinz Jakob
10.50 Proximal aortic dissection – the emerge of TEVAR, George Asimakopoulos
11.00 Staged repair of complex aortic dissection – safer or superfluous? Julien Gaer
11.10 Retrograde aortic dissection after TEVAR: incidence, risk factors, precautions and treatment, Firas Mussa
11.20 Positive family history of aortic dissection dramatically increases dissection risk in family members, John Elefteriades
11.30 Clinical outcomes of TBADs in patients with connective tissue diseases (Marfan, Loeys-Dietz, etc.) are worse than in those without, Firas Mussa
11.40 Case presentation and discussion: severe lower extremity malperfusion in a patient with acute type A dissection, what is the priority? Vincent Tchana-Sato
11.50 Type B aortic dissection in the patient with MYLK variants. What is the best solution: TEVAR or open repair? Vincent Tchana-Sato
12.00 Questions to experts and panel discussion
12.30 Lunch break

TEVAR for TAA
Eric Verhoeven, Hans-Henning Eckstein
13.30 Open surgical conversion after TEVAR: incidence and treatment options, Domenico Baccellieri
13.39 Spinal cord ischemia in TAAA branched grafting, Eric Verhoeven
13.48 CSF drainage in TEVAR: anesthetic considerations, Gregory Hans
13.57 Neuromonitoring using motor and somatosensory evoked potentials in aortic surgery, John Elefteriades
14.06 Is there an increased risk to more complex fenestrated EVAR? Eric Verhoeven
14.15 Fenestrated and branched grafts: lessons after four years of the Windows trial, Jean-Pierre Becquemin
14.24 Consensus exercise on management of thoracic and thoracoabdominal aortic aneurysms in the United Kingdom, Srinivasa R. Vallabhaneni
14.33 Type B dissection: update on indications and results using a pragmatic policy, Fabien Koskas
14.42 Ask to experts and panel discussion

Potpourri related with aortic diseases
Colin D. Bicknell, Apostolos Tassiopoulos
15.00 Radiation protection for patient and staff during routine EVAR and TEVAR procedures, Miltiadis Matsagkas
15.08 Management aortic coarctation in 2016: surgery vs endovascular treatment, Colin D. Bicknell
15.16 Management of graft infection after EVAR-TEVAR. Can PET-CT predict the outcome of prosthetic graft infections? Natzi Sakalihasan
15.24 Cumulative incidence of graft infection after primary prosthetic aortic reconstruction in the endovascular era, Jan Blankensteijn
15.32 Extra anatomic bypass for congenital and acquired disorders of the thoracic aorta: indications, technique, results, Valery Arakelyan
15.47 Keynote lecture. Medical errors during endovascular treatment for aortic diseases. How can we avoid them? Colin D. Bicknell
15.57 Discussion

Short communications from selected papers
16.20 • Incidence, treatment and long-term clinical outcome in patients with aortic graft infections, Jennifer Pettersson
16.25 • Sex differences in outcomes after AAA repair in the United Kingdom, Matthew Bown
16.30 • Explantation of a fenestrated abdominal endograft with autologous venous reconstruction for infection, Catherine Terry
16.40 Coffee break
Friday September 16

I Generalities on EVAR
Nicos Labropoulos, Isabelle Van Herzeele

17.10 Impact of geometry and respiratory-induced deformation during snorkel/chimney and fenestrated endografts for complex abdominal aortic aneurysms, Ronald Dalman

17.20 Flow characteristics of Type II endoleaks. Does it matter? Nicos Labropoulos

17.30 Invisible endoleak after stent graft: a ghost or a myth? Eric Allaire

17.40 Apposition of the endograft post-EVAR. Improved technique to calculate and its importance to predict failure, Jean-Paul de Vries

17.50 Patients’ compliance with post-EVAR follow-up and its impact on the outcome, Athanasios Giannoukas

18.00 Early and long-term outcomes after open or endovascular repair for abdominal aortic aneurysms in high-risk patients, Domenico Palombo

18.10 Renal function is the main predictor of acute kidney injury after endovascular abdominal aortic aneurysm repair, Thanos Saratzis

18.20 Is there a role for use of endoanchors in EVAR or TEVAR procedures? Apostolos Tassiopoulos

18.30 Profile of secondary interventions after EVAR in current practice: how are they triggered and what are the implications for surveillance? Srinivasa R. Vallabhaneni

18.40 Keynote lecture. Decision making in AAA repair in 2016: open or endo? Jan Blankensteijn

18.50 Case presentation, Isabelle Van Herzeele

19.00 Questions to experts and panel discussion

19.15 End of the sessions
Saturday September 17

Risk stratification in BAV aortopathy: new concepts
Allessandro Della Corte, Simon Body
08.30 Genotype-based risk stratification of BAV disease: dream or reality? Simon Body
08.40 Implementing phenotype-based risk stratification of BAV aortopathy in surgical practice, Evaldas Girdauskas
08.50 Structural finite element modelling of the bicuspid root to understand disease progression, Emiliano Votta
09.00 Functional imaging of the BAV aorta to predict aortopathy progression, Malenka Bissell
09.10 Identifying circulating biomarkers of BAV aortopathy risk, Allessandro Della Corte
09.30 Questions to experts and discussion

Short communications from selected papers
09.35 Aortopathy in patients with a bicuspid aortic valve: a process beyond normal cardiovascular ageing, Nimrat Grewal
09.40 The role of hemodynamics and shear stress on the ascending aortic wall in patients with a bicuspid aortic valve, Nimrat Grewal

09.45 Coffee break

Ascending aorta
John Elefteriades, Jean-Olivier Defraigne
10.15 The pathology of thoracic aortic aneurysm, Per Eriksson
10.25 Twenty-five year outcome of composite graft aortic root replacement: near “curative” impact on aortic root disease, John Elefteriades
10.35 Is there really research-based evidence for a guideline dimension for ascending aortic aneurysm repair? Simon Body
10.45 How to classify the dilatations of the ascending aorta? Allessandro Della Corte
10.55 Modeling of predissection aortic size in acute type A dissection: more than 90% fail to meet the guidelines for elective ascending replacement, Rita K Milewski
11.05 Management of aorto-ventricular tunnels: a rare cause (disregarded) of the heart failure in occidental countries. Single center experiences in HCMC, Vietnam, Dung Le Huu, Natzi Sakalihasan
11.15 Questions to experts and discussion

11.30 Industry sponsored symposium (See page 17)

12.30 Lunch break

Aortic arch
Firas Mussa, Jan Brunkwall
13.30 Supraaortic debranching and TEVAR for arch aneurysms – is it a valid alternative for open surgery? [Single center series on > 50 pts], Hans-Henning Eckstein
13.40 Branched endograft vs. chimney techniques for treating complex arch lesions. Which is best, when and why, Firas Mussa
13.50 Update on total arch endovascular repair, Rachel Clough
14.00 Various cardiac access routes to treat ascending aortic and arch lesions: advantages and limitations, Firas Mussa
14.10 Does the bovine arch have any influence on the outcome of arch stentgrafting in dissections? Jan Brunkwall
14.20 Distal aortic reintervention after surgery for acute DeBakey type I or II aortic dissection: open vs. endovascular repair, Rita K. Milewski
14.40 Discussion

Short communications from selected papers
14.50 Deep hypothermia with retrograde cerebral perfusion – as method of brain protections in ascending aorta and arch aneurysms surgery, Vitalii Kravchenko
14.55 Aneurysm at the site of repair of coarctation of aorta: frequency, methods of treatment, results, Vitalii Kravchenko

15.00 TAVI indications, Luc Piérard
15.10 New imaging modalities for assessment of TAVI procedure and results, Helena Dulgheru
15.20 Critical analysis of recent registries and randomized trials, Victor Legrand
15.30 Choice of the best transcatheter site for implantation, Marc Radermecker
15.40 Off label indications: where are we? Thomas Modine
15.50 Antithrombotic treatment: DAPT or OAC? Pascal Vranckx
16.00 Rapid deployment aortic bioprosthesis in patients with small aortic annulus, Frédéric Collart
16.10 Valve fair: review of actual and future devices, Peter Frambach
16.20 New insight of percutaneous native aortic valve resection prior to TAVI, Parla Astarci
16.30 Sutureless aortic valve replacement: worldwide experience, Bart Meuris
16.40 Place of loco-regional anesthesia in minimal invasive aortic valve surgery: how I do it?, Öztekin Oto
16.50 Case presentation and discussion: valve thrombosis after transcatheter aortic valve implantation, Rodolphe Durieux
17.00 Discussion
17.10 Closing remarks & Awards ceremony
17.30 Adjournment
• Adventitial adipogenic degeneration: an unidentified contributor to aortic wall weakening in the abdominal aortic aneurysm

• PET-TC utility to assess the abdominal aortic aneurysm growth and its relationship with changes in energetic metabolism
  Angel Galindo, Guillermo Moñux, Javier Modrego, Roberto Delgado, Manuela Maria Hernandez, Antonio Jose Lopez-Farre, Francisco Javier Serrano

• Evidence of intimal tear in aortic intramural hematoma
  Gianfranco Filippone, Rosalba Franchino, Alessandro Ricasoli, Vincenzo Argano

• The application of metabolic profiling to aneurysm research
  Michele Greco, Mahim Qureshi, Vorkas Panagiotis, Elaine Holmes, Alun H Davies

• Preoperative fibrinogen levels and early outcome following endovascular repair of ruptured abdominal aortic aneurysms
  Christos Karkos, Aristotelis Ilantzis, Christina Papadimitriou, Ioannis Pliatsios, Dimitrios Pelekas, Maria-Afroditi Mitka, Konstantinos Papazoglou

• Inflammation as a predictor of abdominal aortic aneurysm growth and rupture: a systematic review of imaging biomarkers
  Hamid Jalalzadeh, Reza Indrakusuma, R.N. Planken, D.A. Legemate, M.J.W. Koelemay, Ron Balm

• The association of mmp9 and mmp13 functional genetic polymorphisms and abdominal aortic aneurysm in a Greek population
  Georgios Makrygiannis, Evanthia Mourmoura, Konstantinos Spanos, Nikolaos Roussas, Aspasia Tsezou, Athanasios Giannoukas

• Can aortic root replacement with a graft affect cardiac function in patients with marfan syndrome?
  Laura Muino Mosquera, Katrien François, Thierry Bové, Daniel De Wolf, Julie De Backer

• Cholesterol precursors in patients with AAA
  Miroslav Prucha, Petr Sedivy, Petr Stadler

• Gene expression signature in patients with abdominal aortic aneurysm
  Miroslav Prucha, Petr Sedivy, Petr Stadler, Pavel Zdrahal

• The natural history of a large aorta is greater cardiovascular risk
  Matthew Bown, David Sidloff, Athanasios Saratzis

• Overview about the value of functional imaging in the management of aortitis
  Bruls Samuel, Courtois Audrey, Nusgens Betty, Delraigne Jean-Olivier, Delvenne Philippe, Hustinx Roland, Moutschen Michel, Sakalihasan Natzi
General information

Meeting venue
Crowne Plaza Hotel
9-11, rue du Mont St Martin, Liège, Belgium
www.crowneplazaliege.be

HOTELS
1. Crowne Plaza - Congress venue
9-11, rue du Mont St Martin
www.crowneplazaliege.be

2. Pentahotel Liège**** (5 min. walk)
100, bd de la Sauvenière
www.pentahotels.com

3. Ibis Liège Centre Opéra*** (5 min. walk)
41, place de la république Française
www.ibis.com

REGISTRATION & INFORMATION DESK
Thursday ...................... 07.30 - 19.00
Friday ....................... 08.00 - 19.30
Saturday ..................... 08.00 - 17.30

EXHIBITION HOURS
Thursday ...................... 09.30 - 19.00
Friday ....................... 09.00 - 19.30
Saturday ..................... 09.00 - 14.00

EXHIBITORS

<table>
<thead>
<tr>
<th>BOOTH</th>
<th>INDUSTRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MEDTRONIC</td>
</tr>
<tr>
<td>2</td>
<td>COOK MEDICAL</td>
</tr>
<tr>
<td>3</td>
<td>VITALITEC</td>
</tr>
<tr>
<td>4</td>
<td>BARD</td>
</tr>
<tr>
<td>5</td>
<td>JOHNSON &amp; JOHNSON MEDICAL</td>
</tr>
<tr>
<td>8</td>
<td>EUROSETS</td>
</tr>
<tr>
<td>11</td>
<td>ST JUDE MEDICAL</td>
</tr>
<tr>
<td>12</td>
<td>HOSPITHERA</td>
</tr>
<tr>
<td>13</td>
<td>MAQUET</td>
</tr>
<tr>
<td>14</td>
<td>LIVANOVA</td>
</tr>
<tr>
<td>16</td>
<td>EDWARDS</td>
</tr>
</tbody>
</table>
EVENT COORDINATORS’ CONTACTS

Christine Arzouyan
General organization
Mobile: +33 613 96 08 70
carzouyan@divine-id.com

Cyrielle Launoy
Faculty
claunoy@divine-id.com

Véranne Bergeron Moreau
Executive manager
Mobile: +33 621 78 87 16
vbergeron@divine-id.com

LOCAL CONTACT

Geneviève Péters
Scientific program
CHU Liège • Belgium
Tel.: +32 4 366 43 49
genevieve.peters@chu.ulg.ac.be

ORGANIZATION

divine [id] agency
17, rue Venture • 13001 Marseille • France
Tel.: +33 491 57 19 60
Fax: +33 491 57 19 61
info@divine-id.com
www.divine-id.com